Mark Yarchoan

Medicine & Life Sciences

1. Adenocarcinoma 52%
2. Alzheimer Disease 46%
3. atezolizumab 19%
4. B-Lymphocytes 21%
5. Biliary Tract Neoplasms 45%
6. Biomarkers 38%
7. cabozantinib 41%
8. Cancer Vaccines 25%
9. Cell Death 15%
10. Cholangiocarcinoma 35%
11. Clinical Trials 28%
12. Colitis 20%
13. Colorectal Neoplasms 18%
14. Fibrolamellar hepatocellular carcinoma 34%
15. GDC-0973 24%
16. Granzymes 15%
17. GVAX vaccine 21%
18. Hepatocellular Carcinoma 100%
19. Homoharringtonine 16%
20. Immunity 61%
21. Immunotherapy 93%
22. Ipilimumab 35%
23. Irinotecan 14%
24. Ligands 22%
25. Liver Neoplasms 26%
26. Lymphocyte Count 21%
27. Mitogen-Activated Protein Kinase Kinases 57%
28. Mutation 21%
29. Neoplasms 99%
30. Nivolumab 41%
31. olaparib 15%
32. Pancreatic Neoplasms 39%
33. Pathology 15%
34. pazopanib 14%
35. pembrolizumab 18%
36. Physicians' Practice Patterns 15%
37. pramlintide 17%
38. Programmed Cell Death 1 Receptor 14%
39. Progression-Free Survival 21%
40. Regulatory B-Lymphocytes 15%
41. Sorafenib 15%
42. Survival 31%
43. T-Lymphocytes 54%
44. Therapeutics 37%
45. trametinib 15%
46. Tumor Burden 57%
47. Tumor Microenvironment 53%
48. Turcot syndrome 14%
49. Vaccines 23%